Insights
News, analysis, and commentary across healthcare valuation, strategy, and innovation.
When AI Does the Work: Is Your wRVU Compensation Plan Still Defensible in 2026?
AI scribes, CMS's 2026 efficiency adjustment, and benchmark lag are changing how wRVU compensation plans should be evaluated for FMV and commercial reasonableness.
Academic Medical Centers Are Becoming Data Licensors - And Most Aren't Ready for What That Means
The quiet commercialization shift that's rewriting healthcare compliance Ten years ago, if you wanted to commercialize innovation from an academic medical center, you'd wait for a…
QSBS for Healthcare MSOs: Why Your Management Fee Formula Might Be Killing Your Exit Strategy
How a poorly structured service agreement can inadvertently disqualify tens of millions in tax-free gains under IRC §1202 If you're building a healthcare MSO with an eye toward a…
From Stipend to Service: A Modern Approach to Valuing Clinical Trial Participation
A pharmaceutical company is designing a Phase III diabetes trial. The protocol calls for participants to complete detailed questionnaires at enrollment and then quarterly for nine…
The Hidden Compliance Risk in Paying Community Partners for Patient Screenings
Healthcare organizations increasingly rely on community-based organizations to identify and screen eligible patients for specialized programs, but paying CBOs per successful enrollment can look dangerously close to paying for referrals without proper FMV documentation.
From Billboards to Clicks: Valuing Digital Health Marketing in the Age of Compliance
Digital health founders face a critical compliance challenge: structuring marketing partnerships that drive growth without crossing into prohibited referral payments. Learn how to value advertising services—not patient outcomes—using defensible FMV methodologies.
When Is Margin Appropriate? A Framework for Anesthesia Subsidy Valuation (Part 2)
Part 2 of our anesthesia subsidy valuation series explores when enterprise margin is justified, and how to document it credibly in fair market value analyses.
Beyond the FTE: A Deep Dive into the Complex World of Anesthesia Subsidy Valuation (Part 1)
An in-depth exploration of how hospitals can credibly model anesthesia coverage costs and defend fair market value in today's complex subsidy environment.
Beyond the Balance Sheet: Why Specialty Expertise is Crucial in Physician Practice Valuation
Physician practice valuation requires more than generic financial formulas. Specialty-specific expertise is essential to produce credible, defensible FMV opinions.
Beyond Reputation: A Defensible Framework for Key Opinion Leader Compensation
Key Opinion Leader (KOL) compensation in life sciences is under intense regulatory scrutiny. Learn how an attribute-based FMV framework ensures objectivity, compliance, and defensibility.